跳至主要内容
临床试验/NCT06117293
NCT06117293招募中不适用

Safety and Efficacy Evaluation of the Mosaic Ultra Device

LUTRONIC Corporation6 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
6
主要终点
Photographic Assessment

研究概览

简要总结

Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Non-smoking, Male or Female
  • Age 18 - 60 years old
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated.
  • Participants who are willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  • OPTIONAL - Participants who are willing to undergo biopsies.

排除标准

  • Previous surgical or cosmetic procedure to the target area in the last 6 to 12 months that could interfere with the treatment procedure
  • A study participant must not be pregnant or have been pregnant in the last 3 months
  • A recent history of smoking (6 months)
  • Presence of an active skin disease or condition that may affect wound healing (ie. diabetes myelitis; connective tissue disease; radiation therapy; or chemotherapy)
  • Seizure disorder caused by bright light
  • A history of thrombophlebitis
  • A history of acute infections
  • A history of heart failure
  • Cancer, malignant disease, skin pathology, condition, or allergic reactions that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during, or after treatments
  • Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E, or anti-inflammatories within 2 weeks prior to treatment
  • Intolerance or allergy to medications that could be prescribed before or after the procedure (eg, antibiotics, anesthesia)
  • A history of keloids
  • A history or evidence of poor wound healing
  • A history of coagulative disorder or current use of anticoagulant drugs within 2 weeks of study participation
  • Use of steroids within 2 weeks of study treatments
  • Patients with implanted pacemaker or defibrillator, or metal pins, or prosthetic joints within 4 cm of treatment area
  • History of psychoneurosis and/or a history of alcohol or drug abuse

结局指标

主要结局

Photographic Assessment

时间窗: 90-day Follow-Up

Evaluation of Randomized Before Treatment and 3-Month Follow-Up Images by Blinded Evaluators

次要结局

  • Safety Assessment(up to 90 days post final treatment)
  • Physician Satisfaction(30-day and 90-day Follow-Up)
  • Physician Clinical Global Aesthetic Improvement Scale(30-day and 90-day Follow-Up)
  • Coagulation Zone Measurements(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Tissue Reepithelization(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Subject Satisfaction(30-day and 90-day Follow-Up)
  • Subject Clinical Global Aesthetic Improvement Scale(30-day and 90-day Follow-Up)
  • Epidermal Inflammatory Response(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)
  • Dermal Inflammatory Response(Baseline, Immediate Post Treatment, 4 Days Post, 14 Days Post, 21 Days Post)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Safety and Efficacy Evaluation of the Mosaic Ultra... | 临床试验